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K. Rabe,3 G. Coppi,4 R. Moratto,4 F.-J. Hoffmann,5 G.C. Schuler1 and G. Biamino11University of Leipzig, Heart Center, Leipzig, Germany, 2Cardiology Department, Hospital of Mirano, Mirano,
Italy, 3Center for Cardiology and Vascular Intervention, Frankfurt, Germany, 4Department of Vascular
Surgery, Hospital of Modena, Modena, Italy, and 5Hospital Neunkirchen, Neunkirchen, GermanyObjectives. This report evaluates the feasibility and efficacy of an endovascular blood flow blockage technique to prevent
intracerebral embolization of plaque debris during carotid artery stenting.
Methods. Forty-two patients were enrolled in five clinical sites in Germany and Italy with either an asymptomatic internal
carotid artery stenosisR75% (mean 87%) or a symptomatic stenosisR60% (mean 85%). Cerebral protection during the
stenting procedure was achieved using an endovascular clamping technique, obtained by occlusion of the external and
common carotid artery via two independently inflatable balloons integrated in the Mo.Maw system. Blood with particulate
plaque debris was aspirated before flow was restored. The patient’s clinical and the neurological status were assessed during
intervention, at discharge, and at 3 months follow-up.
Results. Stenting was performed in all but one patient. The mean flow occlusion time was 10.6G6.5 min. Transient
clamping intolerance was observed in five patients (12%). In two patients, neurological deficits persisted for 2 and 12 h,
respectively. Two minor strokes (4,7%) occurred at 5 and 72 h after the procedure. No major strokes or deaths were observed
at 3 months follow-up.
Conclusions. This first clinical experience with the Mo.Maw device substantiates the feasibility of endovascular clamping
in preventing cerebral embolization during carotid artery stenting.Keywords: Carotid arteries; Carotid artery stenting; Cerebral protection device; Endovascular clamping.Introduction
Cerebral protection devices currently used for carotid
artery stenting are based on either balloon induced
distal blockage of the ICA blood flow, filters deployed
distally to the stenosis or proximal balloon occlusion of
both external (ECA) and common carotid artery
(CCA). The novel Mo.Maw device emulates a surgical
clamping technique by stagnating blood flow during
the procedure and aspirating particulate debris before
the restoration of blood flow during and/or at the end
of the procedure. Here, we report the first clinical
experience with this embolic protection system inves-
tigating its feasibility and safety.ing author. K.-W. Diederich, Clinic of Internal Medi-
ogy, University of Leipzig–Heart Center, Stru¨mpellstr.
pzig, Germany.
: k.diederich@medizin.uni-leipzig.de.
0629+ 05 $35.00/0 q 2004 Elsevier Ltd. All rights reserMaterials and MethodsDevice
The Mo.Maw device (Invatec s.r.l., Roncadelle (BS),
Italy), now CE marked, integrates the functional
aspects of cerebral protection and guiding catheters
in a single system. The basic component of the system
is a 100 cm long catheter with a 2.1 mm (0.081 in.)
central lumen that is wide enough for the insertion of
interventional devices as well as the effective aspira-
tion of particles. The exit port of the working channel
is located between two independently inflatable low
pressure compliant balloons (Fig. 1) that permit
endovascular clamping of both the CCA (%13 mm)
and the ECA (%6 mm). Antegrade blood flow is
blocked before a guide wire is advanced across the
lesion. Any particulate debris generated during wire
advancement, stent advancement, pre-dilatation, stent
deployment, or post-dilatation remains stagnate in theEur J Vasc Endovasc Surg 28, 629–633 (2004)
doi:10.1016/j.ejvs.2004.08.012, available online at http://www.sciencedirect.com onved.
Fig. 1. The endovascular clamping device (Mo.Maw, Invatec s.r.l., Roncadelle (BS), Italy).
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blood flow.Patients
Forty-two patients (30 males, 12 females) were
enrolled in five clinical sites in Germany and Italy
(Leipzig 20, Frankfurt 10, Neunkirchen 6, Mirano 4,
Modena 2). The inclusion criteria were the presence of
an asymptomatic ICA stenosis R75% or a sympto-
matic stenosisR60%. Patients were excluded from the
study if they presented with a total occlusion of the
contralateral ICA, had a stroke or acute myocardial
infarction within 2 weeks prior to the intervention, had
additional relevant lesions of the ECA and proximal
CCA, presented with ICA stenoses after radiation or
induced by an external tumor, had a known allergy to
contrast media, renal insufficiency (Creatine O
2.5 mg/dl), documented coagulopathy, or had vessel
anatomy that precluded an endoluminal approach.
The local ethics committee at each participating siteFig. 2. Angiogram frames during carotid stenting using the Mo
(black arrow) visible in the CCA and the distal balloon (white
Dye stagnation after balloon inflation. (C) advancement of th
deployment (Carotid Wallstent 9!30 mm). (E) Post-dilatation
deflated after aspiration of blood.
Eur J Vasc Endovasc Surg Vol 28, December 2004approved the study and all patients gave informed
consent.Intervention
Patients received clopidogrel (300 mg) the day before
the procedure and aspirin (500 mg IV) immediately
before intervention if they were not on clopidogrel
(75 mg/d) and aspirin (100 mg/d) already for at least
10 days. Diagnostic angiography with a 5 F catheter
was performed to validate the ICA stenosis. A soft
angled, coated guidewire and the diagnostic catheter
were then gently navigated into the ECA. The soft
guidewire was exchanged for a stiff 0.035 in. wire and
the 5 F sheath was replaced by an 11 F, 25 cm long
sheath. 10,000 IU heparin were administered. The
Mo.Maw system was advanced over the stiff wire
until the radiopaque marker for the distal balloon was
located in the ECA, around 0.5–1 cm beyond the
bifurcation and proximal to or at the thyroidal branch
(Fig. 2(A)). The distal ECA balloon was inflated to.Maw system. (A) device in situ. Markers of proximal balloon
arrow) visible in the ECA at the level of the ICA stenosis. (B)
e 0.014 in. guide wire under protection. (D) Primary stent
with a 6 mm balloon. (F) Final angiogram with balloons
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ment. A small valve at the tip of the system prevented
reverse flow from the ECA as the stiff guide wire was
removed. After the proximal balloon was inflated, a
few millilitre contrast media was injected to verify the
effective blockage of the antegrade flow (Fig. 2(B)).
Immediately after documentation of flow blockage, the
blood-dye mixture was aspirated through the working
channel. Blood pressure in the CCA proximal to the
lesion (‘stumppressure’),maintainedpredominantly by
the contralateral perfusion, was carefully monitored. A
0.014 in. guidewire was navigated through the lesion
(Fig. 2(C)). Atropine was administered before a balloon
or stent entered the ICA. Following pre-dilatationwith a
4 mm balloon, an appropriately sized, self expanding
stent (Carotid Wallstentw, Boston Scientific Inc. or
Acculinkw, Guidant Inc.) was deployed (Fig. 2(D)).
Post-dilatation was performed with a 4–7 mm!20 mm
balloon (Submarine Rapidow, Invatec s.r.l. or Vivaw,
Cordis) dependingonvessel size (Fig. 2(E)). Intermittent
aspirationafterpre-dilatationandstentdeploymentwas
performed at the discretion of the operator. In cases
where the patient developed neurological signs of
intolerance, the procedure was performed in a step by
step manner. After pre-dilatation or stent deployment,
followed by blood aspiration to remove particulate,
blood flow was restored until symptoms normalized.
Clamping was then re-established for the remaining
steps. In all cases, at least 40 mlbloodwas aspiratedwith
a standard syringe before restoration of flow. The
aspirates were filtered through a sieve to collect the
plaque debris. After deflation of the ECA balloon,
followed by the CCA balloon, the final result was
documented (Fig. 2(F)). An intracranial angiogram in
twoperpendicular planes concluded the procedure. The
Mo.Ma. system was then removed under fluoroscopy.
The patient’s neurological status was monitored
throughout the procedure by continuous communi-
cation and testingmotor function. The groin was closed
by compression over 4 h. In cases of neurological deficits
during or after procedure the patients underwent serial
CTor MRA scans and neurological examinations.Follow up
The post-procedural hemodynamic and neurological
status was carefully controlled. Repeat examinations
according to the NIH Stroke Scale and Duplex
ultrasound of the treated vessel were performed
before discharge, 30 days after the procedure and at
3 months follow-up. The patients were discharged on
clopidogrel (75 mg/d for 1 month) and continuous
aspirin (100 mg/d).ResultsLesion characteristics
The ratio of left to right sided lesions was 22/20. Forty-
one (97.6%) lesions were de novo and one patient
presented restenosis after endarterectomy. The mean
lesion length was 14.3G6.0 mm. The mean stenosis
diameter was 85.1G8.0% by visual estimate of
angiogram according to ACCAS criteria (ratio
between diameter of distal ACI and diseased area in
the worst projection). In 11 patients (26.2%), a history
of neurological symptoms was correlated to the target
lesion. 13 patients (30.9%) had a significant stenosis (O
50%) of the contralateral ICA.Procedure outcome
TheMo.Maw device was successfully used as intended
and stenting of the stenosed ICAwas performed in all
but one patient. In this case, the complex anatomy of
the arch prevented the stiff wire from advancing into
the right ECA, a precondition to navigate the Mo.Maw
system into position. A CarotidWallstentwwas used in
38 cases (90.5%) and an Acculinkw stent was used in
three cases (7.1%). The mean time of flow blockage
(clamping time) was 10.6G6.5 min. Particulate debris
was grossly visible in the filtered aspirate in 32 of the
41 completed procedures (76.1%). The mean duration
of the total procedure was 51.0G28.3 min. Nominor or
major strokes were observed during the procedure or
as long the patients were in the vascular suite.
Transient neurological deficits (‘clamping intolerance’)
were observed in three patients (7.2%) who presented
with symptoms ranging from limb weakness to total
loss of consciousness in one patient during aspiration
after post-dilatation. In two (4.8%) patients neurologi-
cal deficits occurred during intervention not reversible
within 20 min. These two events, patients suffered
from facial paresis that lasted for 2 h and brachiofacial
paresis that resolved after 12 h, respectively, appear to
be of multifactorial causes and may be classified as
TIA’s. The serial CT-scan in these patients displayed
no new lesions.
In one case, a minor stroke, likely embolic, occurred
5 h after stenting of an asymptomatic left ICA. The
patient developed right-sided hemiparesis. The
patient was discharged after 14 days with minor
impairments persisting at 3 months follow-up
(NIHSSSZ2). Another patient manifested distal
ischemic symptoms on the punctured right leg 1 day
after carotid stenting. Transbrachial angiography
confirmed the suspected occlusion of the distal SFAEur J Vasc Endovasc Surg Vol 28, December 2004
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day after local thrombolysis with rtPA, the patient
developed frontolobal intracranial bleeding as demon-
strated by CT scan. The hemorrhage was evacuated
surgically and the patient recovered completely
(NIHSSSZ0!) with only distinct changes in a sensitive
personality test at 3 months follow-up. Patients were
discharged after median of 2 days (range 2–14 days).Follow up
All patients completed the 30 days as well as the 3
months follow-up without any further event.Discussion
The concept of endovascular clamping has unique
technical advantages over distal balloon occlusion or
filter protection devices used for cerebral protection
during carotid artery stenting. First, endovascular
clamping provides neuroprotection before the stenosis
is ‘touched’ by any device, including the wire. Second,
after deploying the stent, using the Mo.Maw system, as
much blood can be aspirated as is necessary to remove
all particulate debris. A third advantage of endovas-
cular clamping may be that full stagnation of blood
flow is more easily confirmed andmore stable than the
precise, coaxial alignment of filters to the vessel wall.
In our experience, the Mo.Maw system was effective
even in cases where the superior thyroid artery was
not excluded by the distal balloon. In these cases, the
back-flow from the superior thyroid artery did not
cause washout of contrast dye. In sporadic procedures
controlled by transcranial Doppler no high intensity
transitory signals (HITS) were registered during flowTable 1. Impact of embolic protection devices on the adverse event r
First author Ref no. Proc [n] Protection
devices u
Henry 1 53 Guardwir
Parodi 2 46 Three diff
Reimers 3 88 Three diff
filters
Al-Mubarak 4 164 Neuroshie
Mednova
Schlueter 5 102 Guardwir
Castriota 6 275 Different
Macdonald 7 150 Neuroshie
Adami 8 30 PAES
Cremonesi 9 442 Different
Reimers 10 753 Different
and occlu
devices
This study 42 Mo.Maw
Eur J Vasc Endovasc Surg Vol 28, December 2004blockage, even in cases where the superior thyroid
artery was not covered. In addition, proximal occlu-
sion with the Mo.Maw system can be used in cases
where an ICA with severe distal tortuosity precludes
the safe insertion of distal protection devices.
The ‘Parodi anti-embolism system’,9 shares the
principle of occluding the ECA and CCA by balloons.
However, there are distinct differences between the
Mo.Maw system and the ‘Parodi anti-embolism sys-
tem.’ First, the Mo.Maw device is a single sheath
placed in a single advance over the stiff wire. Second,
the Mo.Maw system does not rely on the establishment
of flow reversal, which is not possible to sustain
throughout the entire procedure, as during stent
advancement, placement, delivery, and post-dilata-
tion. Further, flow blockage is easily confirmed by dye
injection and complete blood aspiration is clearly
visible.
Although this study was not powered to show
equivalence to any other protection device, its com-
plication rate is congruent with other studies investi-
gating the impact of embolic protection devices on the
adverse neurological event rate (Table 1).
One major concern with endovascular clamping,
and shared with all occlusive devices, is the potential
occurrence of ‘clamping intolerance’, or transient
ischemic deficits, during flow blockage. In this study
‘clamping intolerance’ appeared in five patients (12%).
In all of these cases the measured stump pressure,
maintained by the collateral circulation, was below
35 mmHg. In two patients, which have to be classified
as TIA’s, with persisting neurological deficits (2 and
12 h), the systolic blood pressure had dropped below
60 mmHg after stent deployment and post-dilatation.
This indicated that the most probable reason for the
persisting deficits was the stimulation of the carotidate
sed
Procedural
stroke/death
rate (%)
30 Days major
stroke/death
rate (%)
30 Days all
stroke/death
rate (%)
ew 1.8 (retinal)
erent 2.2
erent 1.2 0 1.2
ldw,
w
2.0
ew 3.1
filters 1.3
ldw 2.7 2.7 4.0
0 0 0
1.1 3.4
filters
sive
2.2 1.2 3.3
0 0 4.7
Endovascular Clamping in Carotid Stenting 633sinus followed by cardiovascular depression and not
embolization of plaque debris.
The occurrence of ‘clamping intolerance’ may be
minimized by administration of dopamine, if necess-
ary, and by staging of the procedure where flow is
restored after each step followed by aspiration.
This first clinical experience demonstrates that the
Mo.Ma system is feasible, can be placed and retrieved
safely, followed by successful stenting and the
effective aspiration of particulate debris. Furthermore,
the promising concept of endovascular clamping may
be effective in the prevention of cerebral embolization
during carotid artery stenting. Large controlled trials
are required to confirm this preliminary result.References
1 HenryM, AmorM, Henry I et al. Carotid stenting with cerebral
protection: first clinical experience using the percusurge guard-
wire system. J Endovasc Surg 1999;6:321–331.
2 Parodi JC, La Mura R, Ferreira LM et al. Initial evaluation of
carotid angioplasty and stenting with three different cerebral
protection devices. J Vasc Surg 2000;32:1127–1136.
3 Reimers B, Corvaja N,Moshiri S et al. Cerebral protection with
filter devices during carotid artery stenting. Circulation 2001;
104:12–15.4 Al-Mubarak N, Colombo A, Gaines PA et al. Multicenter
evaluation of carotid artery stenting with a filter protection
system. J Am Coll Cardiol 2002;6(39):841–846.
5 Schlu¨terM, Tu¨bler T,Mathey DG et al. Feasibility and efficacy
of balloon-based neuroprotection during carotid artery stenting
in a single-center setting. J Am Coll Cardiol 2002;40:890–895.
6 Castriota F, Cremonesi A, Manetti R et al. Impact of cerebral
protection devices on early outcome of carotid stenting.
J Endovasc Ther 2002;9:786–792.
7 Macdonald S, McKevitt F, Venables GS et al. Neurological
outcomes after carotid stenting protected with the neuroshield
filter compared to unprotected stenting. J Endovasc Ther 2002;
9:777–785.
8 Adami CA, Scuro A, Spinamano L, Galvagni E,
Antoniucci D, Farello GA, Maglione F, Manfrini S,
Mangialardi N, Mansueto GC, Mascoli F, Nardelli E,
Tealdi D. Use of the parodi anti-embolism system in carotid
stenting: Italian trial results. J Endovasc Ther 2002;9(2):147–154.
9 Cremonesi A, Manetti R, Setacci F et al. Protected carotid
stenting: clinical advantages and complications of embolic
protection devices in 442 consecutive patients. Stroke 2003;
34:1936–1941.
10 Reimers B, Schlu¨ter M, Castriota F, Tu¨bler T, Corvaja N,
Cernetti C, Manetti R, Picciolo A, Liistro F, Di Mario C,
Cremonesi A, Schofer J, Colombo A. Routine use of cerebral
protection during carotid artery stenting: results of a multicenter
registry of 753 patients. Am J Med 2004;116:217–222.
Accepted 31 August 2004Eur J Vasc Endovasc Surg Vol 28, December 2004
